Bridging the Diagnostics Gap – How to Finance Smarter Labs
The UK’s National Health Service (NHS) is increasingly struggling to meet its diagnostic targets. As of August 2025, over 1.6 million people were on waiting…
The UK’s National Health Service (NHS) is increasingly struggling to meet its diagnostic targets. As of August 2025, over 1.6 million people were on waiting…
With agentic AI, the promise is about so much more than process enhancement and greater productivity. It is about redefining a function’s purpose and value,…
Claudia Lehman, Head of Global Pharmacovigilance Operations at Boehringer Ingelheim and Lucinda Smith, ArisGlobal’s Chief Safety Product Officer, chart Boehringer’s shift to AI-powered automation of…
In high stakes, regulated industries the promise of AI is huge – faster decisions, deeper insights, greater efficiency. But so are the risks. When lives, compliance…
AI enabled pharmacovigilance isn’t just about absorbing extra AE case volumes without driving up costs to maintain compliance and mitigate risk. It is also crucial…
How leading biopharm companies like Bayer are standardizing and integrating data for scaling impactful AI. AI use cases are rippling across commercial biopharma, helping companies…
Drug development designed to treat rare disease is both a noble cause and a risky business. Rare diseases are typically deadly, debilitating, and devastating for…
As the cost of developing new therapies continues to rise, pharma executives must turn to technologies that drive better insights into de-risked investments and produce…
Robert Gaertner, Vice President of Quality Strategy Europe at Veeva Systems, discusses the growing importance of connected platforms in ensuring quality in pharmaceutical manufacturing and…
Regulatory workloads now far exceed the pace of company growth, but assigning more people to the tasks isn’t an option, which in turn is driving…